Physician profile
Jonathan T Jacobs
NPI 1164458907
$5,688.16
in general payments reported to CMS, 2019-2025
43 companies · $463 in 2025
The $463 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $111 · 2020: $254 · 2021: $734 · 2022: $1,401 · 2023: $1,421 · 2024: $1,304 · 2025: $463.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,158 · Long Term Medical Supply Or Device Loan: $29.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,157.64 |
| Long Term Medical Supply Or Device Loan | $29.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $937.76 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $848.38 | 2021-2025 | |
| Novo Nordisk INC | $610.76 | 2020-2025 | Ozempic, Rybelsus, Wegovy |
| Amgen INC. | $364.60 | 2019-2025 | Evenity, Repatha, Otezla |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.62 | 2021-2024 | Jardiance, Synjardy, Tradjenta |
| Astrazeneca Pharmaceuticals LP | $288.01 | 2020-2025 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $248.01 | 2022-2025 | Arexvy, Shingrix, Trelegy Ellipta |
| Pfizer INC. | $210.43 | 2020-2025 | |
| Genzyme Corporation | $195.86 | 2022-2023 | |
| Abbott Laboratories | $171.07 | 2021-2024 | Freestyle Libre 2, Freestyle Insulinx, Freestyle Libre 3 |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $169.62 | 2021-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $118.87 | 2022-2025 | Austedo Xr, Ajovy, Austedo Xr |
| Janssen Pharmaceuticals, INC | $102.89 | 2019-2023 | Xarelto |
| Otsuka America Pharmaceutical, INC. | $100.02 | 2021-2024 | Rexulti |
| Boston Scientific Corporation | $98.95 | 2019-2025 | Watchman Flx |
Show all 42 companies
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Jacobs listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.